Amlodipine in the treatment of Raynaud's phenomenon. A double blind placebo-controlled crossover study

Clinical Drug Investigation

Volumn 13, Issue SUPPL. 1, 1997, Pages 126-131

  La Civita, L ^a   Pitaro, N ^a   Rossi, M ^a   Giuggioli, D ^a   Gambini, I ^a   Cini, G ^a   Pasero, G ^a   Ferri, C ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b Istituto di Patologia Medica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON;

EID: 0030742362     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199700131-00022     Document Type: Article

References (23)

1. Rodnan GP. Raynaud's phenomena. In: McCarty DJ, editor. Arthritis and allied conditions. 9th ed. Philadelphia: Lea and Febiger, 1979: 767-9
2. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of Raynaud phenomenon in the general population. J Chron Dis 1986; 39: 423-7
3. Biondi ML, Marasini B, Bassani C, et al. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 1991; 324: 1139-40
4. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36
5. Kallenberg CGM, Pastoor GW, Wouda A, et al. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical sienificance of anticentromere antibodies. Ann Rheum Dis 1982; 41: 382-7
6. Priollet P, Vayssairat M, Housset E. How to classify Raynaud's phenomenon. Long term follow-up study of 73 cases. Am J Med 1987; 83: 494-8
7. Kallenberg CGM. Connective tissue disease in patients presenting with Raynaud's phenomenon alone. Ann Rheum Dis 1991; 50: 666-7
8. Coffman JD. Raynaud's phenomenon. An update. Hypertension 1991; 17: 593-602
9. Cleophas TJM, Niemeyer MG. Raynaud's syndrome, an enigma after 130 years. Angiology 1993; 43: 196-209
10. Wollersheim H, van Zwieten PA. Treatment of Raynaud's phenomenon. Eur Heart J 1993; 14: 147-9
11. Smith CD, McKendry RJR. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982; 2: 1299-1301
12. Smith CR, Rodeheffer RJ. Raynaud's phenomenon: pathophysiologic features and treatment with calcium channel blockers. Am J Cardiol 1985; 55: 154B-7
13. Rupp PAF, Mellinger S, Kohler J, et al. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker. J Rheumatol 1987; 14: 745-50
14. Kahan A, Amor B, Menkes CJ, et al. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double blind trial. Angiology 1987; 38: 333-7
15. Ferri C, Cecchetti R, Cini G, et al. Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases. Clin Rheumatol 1992; 11: 76-80
16. Allen EV, Brown GE. Raynaud's disease: a critical review of a minimal requisites for diagnosis. Am J Med Sci 1932; 183: 187-200
17. Maricq HR. Widefield capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 1981; 24: 1159-65
18. Ferri C, Bernini L, Cecchetti R, et al. Cutaneous and serological subset of systemic sclerosis. Their relevance in diagnosis, severity and prognosis of the disease. J Rheumatol 1991; 18: 1826-32
19. Del Guercio R, Leonardo G, Arpaia MR. Evaluation of postischemic hyperemia on the skin using laser Doppler velocimetry: study on patients with claudicatio intermittens. Microvasc Res 1986; 32: 289-99
20. Russel A, Kappagoda T. Reactive hyperemia in patients with Raynaud's phenomenon. J Rheumatol 1988; 15: 1653-7
21. Fronek A, Johansen K, Dilley RB, et al. Ultrasonographically monitored post-occclusive reactive hyperemia in the diagnosis of peripheral arterial occlusive disease. Circulation 1973; 48: 149
22. Andreozzi GM, Signorelli S, Lo Duca S, et al. Effects of mesoglycan sulfate on the arterial elastic module. Angiology 1987; 8: 593-600
23. Challenor VF, Waller DG, Hayward RA, et al. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology 1989; 40: 122-8